The study to investigate clnicopathological characteristics of superficial esophagogastro junction cancer

The study to investigate clnicopathological characteristics of superficial esophagogastro junction cancer - EGJ_CA_Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025319

Enrollment

200

Registered

2016-12-19

Start date

2016-10-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophagogastro junction cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Siewert type 2 cancer (true cardia cancer: adenocarcinoma located within 1 cm above and 2 cm below the GE Junction) 2) pathological T1

Exclusion criteria

Exclusion criteria: 1) Unevaluable endoscopic images 2) Unevaluable histological findings

Design outcomes

Primary

Measure	Time frame
Difference of clinicaopthological characteristics of superficial esophagogastro junction cancer according to presence and absence of endoscopic gastric corpus mucosal atrophy	—

Secondary

Measure	Time frame
1) Factors associated with endoscopic gastric corpus mucosal atrophy 2) Difference of clinicaopthological characteristics of superficial esophagogastro junction cancer according to presence and absence of Barrett mucosa 3) Difference of clinicaopthological characteristics between EGJ cancer and Barrett cancer 4) Difference of clinicaopthological characteristics between EGJ cancer and gastric cancer in the upper body.	—

Measure

Time frame

1) Factors associated with endoscopic gastric corpus mucosal atrophy 2) Difference of clinicaopthological characteristics of superficial esophagogastro junction cancer according to presence and absence of Barrett mucosa 3) Difference of clinicaopthological characteristics between EGJ cancer and Barrett cancer 4) Difference of clinicaopthological characteristics between EGJ cancer and gastric cancer in the upper body.

—

Countries

Japan

Contacts

Public ContactKazuhiro Katayama

Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Gastrointestinal Oncology

kbyori01@mc.pref.osaka.jp06-6972-1181

Outcome results